market access

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Debates & Insight

The hepatitis C conundrum: balancing cost and affordability

An estimated 2–3% of the world’s population is living with hepatitis C virus (HCV) – a condition that, when left untreated, can cause life-threatening damage to the liver.

Views & Analysis

Going beyond CSR to reach ‘the two billion’

Impact of putting access to medicine at the core of pharma businesses.

Views & Analysis

Commuter Business People Cityscape Corporate Travel Concept

Outcomes-based medicine demands real-world evidence

RWE must become a fundamental accompaniment to traditional RCT data.

Views & Analysis

Effective decision making in early asset development and com...

Addressing the data and evidence gap in the early stages of asset development.

Views & Analysis

Paid medicine. Cost of treatment. Isolated 3D image

A novel UK approach to cancer access: yes, no, or maybe?

Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.

Articles

EFPIA’s director general, Richard Bergström, on market acces...

He says the industry will partner with payers to deliver outcomes-driven, sustainable healthcare, in pharmaphorum's magazine Deep Dive: Market Access.

The hepatitis C conundrum: balancing cost and affordability

Going beyond CSR to reach ‘the two billion’

Outcomes-based medicine demands real-world evidence

Effective decision making in early asset development and com...

A novel UK approach to cancer access: yes, no, or maybe?

EFPIA’s director general, Richard Bergström, on market acces...

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

market access

Editor's Picks